QGEN - QIAGEN N.V.
| Previous Close | 34.83 |
| Open | 34.67 |
| Bid | 34.78 x 800 |
| Ask | 34.79 x 1200 |
| Day's Range | 34.44 - 34.82 |
| 52 Week Range | 25.04 - 43.16 |
| Volume | 1,752,326 |
| Avg. Volume | 2,934,267 |
| Market Cap | 7.881B |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | Feb 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.69 |
- Zacks
ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?
ALXN vs. QGEN: Which Stock Is the Better Value Option?
- Business Wire
QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer
QIAGEN builds on global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer
- Business Wire
QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results
QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results
- Business Wire
QIAGEN Celebrates Surpassing 2,500 Cumulative Placements of QIAsymphony
QIAGEN celebrates surpassing 2,500 cumulative placements of QIAsymphony
- GlobeNewswire
Calibre Scientific Acquires NeXtal Biotechnologies to Further Expand its Protein Portfolio
Calibre Scientific is pleased to announce that it has completed the acquisition of the NeXtal Biotechnologies line of structural biology products from Qiagen NV (QGEN). NeXtal specializes in the production of unique screens and plates for protein crystallization, an important step in the complex process of structural biology studies and structure-based drug design. NeXtal’s products include a comprehensive suite of reliable crystallization screens and proprietary EasyXtal crystallization plates that are currently sold into academic, biotechnology, and pharmaceutical markets.
- Zacks
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.
- Schaeffer's Investment Research
QGEN Calls Pick Up as Stock Recovers
QGEN shares have been making big moves this week
- Benzinga
PreMarket Prep Recap: Qiagen Pulls The Rug Out From Investors Banking On A Deal, Bad Data Equals Bad Price Action For Spectrum Pharmaceuticals
Benzinga's PreMarket Prep show resumed Thursday after a pause for the Christmas holiday. As always, there were a few market movers to cover and two informative interviews. Qiagen Decides Not To Sell When ...
- Benzinga
The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...
- TheStreet.com
Qiagen Plunges After Saying It Won't Pursue a Sale
The genetic testing company will remain a stand-alone business following a review of strategic alternatives.
- MarketWatch
Qiagen stock plunges more than 25% after opting against sale
Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. Qiagen announced last month that it had received "several" entreaties to acquire the molecular-diagnostics specialist, and were exploring the opportunities. Shares, which had been hit hard by a CEO departure and China-related concerns, rebounded on that news. After the shortened Christmas Eve trading session ended, though, Qiagen announced that its management and supervisory boards had opted against a sale and terminated all discussions because "the alternatives to the stand-alone business plan prospects were not compelling." Shares closed Tuesday with a 0.8% increase at $41.47, then dove to less than $31 in after-hours trading following the announcement.
- Business Wire
QIAGEN Concludes Strategic Alternatives Review; Decides to Focus on Stand-Alone Business Strategy to Drive Future Value Creation
QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation
- Simply Wall St.
What Is QIAGEN N.V.'s (NYSE:QGEN) Share Price Doing?
QIAGEN N.V. (NYSE:QGEN), which is in the life sciences business, and is based in Netherlands, received a lot of...
- Zacks
OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?
OSMT vs. QGEN: Which Stock Is the Better Value Option?
- Zacks
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
- Benzinga
The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
- TEST Business Wire Releases
QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch
QIAGEN and DiaSorin receive FDA approval for the LIAISON QuantiFERON-TB Gold Plus Test on LIAISON platforms and begin commercial launch
- GlobeNewswire
ROSEN, A GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. – QGEN
NEW YORK, Nov. 25, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V..
- Zacks
QIAGEN Expands Existing Deal With LabCorp for Better Treatment
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
- Business Wire
QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutions
Seven-year collaboration expands LabCorp’s use of QIAGEN’s QCI platform with QIAGEN’s Human Gene Mutation Database for rare and hereditary workflows
- Zacks
OSMT or QGEN: Which Is the Better Value Stock Right Now?
OSMT vs. QGEN: Which Stock Is the Better Value Option?
- Benzinga
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
- Zacks
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
